HIMS vs TAK โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TAK Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, HIMS trades at 54.0x Forward P/E with -6.4% operating margin (+48.6% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, HIMS sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | HIMS | TAK | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.6B | $67.5B | Larger Scale | TAK |
| Trailing P/E Ratio Valuation | 54.0x | N/M | Lower Multiple | HIMS |
| Forward P/E Ratio Valuation | 54.0x | 12.7x | Lower Multiple | TAK |
| Revenue Growth (YoY) Growth | +48.6% | +6.7% | Higher Growth | HIMS |
| Operating Margin (TTM) Profitability | -6.4% | 16.6% | Higher Margin | TAK |
| Net Profit Margin Profitability | -6.7% | 0.9% | Higher Margin | TAK |
| Return on Equity (ROE) Capital Efficiency | -40.8% | 0.6% | Higher ROE | TAK |
| 52-Week Range Position Momentum | 19% ($14โ$41) | 97% ($14โ$22) | Stronger Trend | TAK |
| Beta / 30D Volatility Risk Regime | 2.61ฮฒ ยท 103% Vol | -0.02ฮฒ ยท 22% Vol | Lower Realized Risk | TAK |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 48.0 / 100 (HOLD) | Higher Composite | HIMS |